Is IBO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IBO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IBO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IBO's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IBO?
Key metric: As IBO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for IBO. This is calculated by dividing IBO's market cap by their current
earnings.
What is IBO's PE Ratio?
PE Ratio
25.8x
Earnings
US$1.17m
Market Cap
US$30.03m
IBO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: IBO is expensive based on its Price-To-Earnings Ratio (25.8x) compared to the US Pharmaceuticals industry average (20.5x).
Price to Earnings Ratio vs Fair Ratio
What is IBO's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
IBO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
25.8x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate IBO's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.